[go: up one dir, main page]

EP1490691A2 - Particules de silicagel luminescentes, spheriques et non autofluorescentes a intensites et frequences d'emission variables - Google Patents

Particules de silicagel luminescentes, spheriques et non autofluorescentes a intensites et frequences d'emission variables

Info

Publication number
EP1490691A2
EP1490691A2 EP03720372A EP03720372A EP1490691A2 EP 1490691 A2 EP1490691 A2 EP 1490691A2 EP 03720372 A EP03720372 A EP 03720372A EP 03720372 A EP03720372 A EP 03720372A EP 1490691 A2 EP1490691 A2 EP 1490691A2
Authority
EP
European Patent Office
Prior art keywords
luminescent
silica gel
substances
particles according
sol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP03720372A
Other languages
German (de)
English (en)
Other versions
EP1490691B1 (fr
Inventor
Detlef P. Müller-Schulte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MagnaMedics GmbH
Original Assignee
Mueller-Schulte Detlef P
MagnaMedics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mueller-Schulte Detlef P, MagnaMedics GmbH filed Critical Mueller-Schulte Detlef P
Publication of EP1490691A2 publication Critical patent/EP1490691A2/fr
Application granted granted Critical
Publication of EP1490691B1 publication Critical patent/EP1490691B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots

Definitions

  • Luminescent, spherical, non-autofluorescent silica gel particles with variable emission intensities and frequencies are compared to determine whether the emission intensities and frequencies.
  • the present invention relates to luminescent, spherical micro- and nanoparticles with variable luminescence intensities, a process for their production and their use.
  • luminescence is defined as the emission of light of the entire spectral range by substances that were previously excited by energy absorption. Fluorescence and phosphorescence also fall under this term.
  • Luminescent substances are now routinely used in the form of fluorescent or phosphorescent substances in the entire field of biochemical and medical analysis or diagnostics for the detection of analytes such as proteins, peptides, toxins or nucleic acids as well as markers for the visualization of cells, cell compartments or for the detection of biological processes.
  • array technology is understood to mean flat glass or polymer supports or substrates - also referred to as biochips - on which a large number of biomolecule probes (nucleic acids, proteins or peptides) of known structure are applied in a grid-like arrangement.
  • biomolecule probes nucleic acids, proteins or peptides
  • luminescent substances mainly affects two classes of substances.
  • One is luminescent molecules, the best known representatives of which are fluorescein, rhodamine, phycoerythrin, coumarin, Cy3, Cy5, TAMRA, ROX, Oregon Green, ethidium bromide, Texas Red and Dabcyl (these are the names consistently for trade names).
  • the other class of compounds are the semiconductor nanocrystals formed primarily from groups IIB and VIA, IIIA and VA or IVA of the periodic table, the best known of which are CdS, CdSe, CdTe, ZnS and ZnSe.
  • quantum dots an interesting alternative to the conventional fluorescent dyes is the fact that the absorption and emission behavior of the quantum dots is size-dependent. In other words: with decreasing Particle size shifts the emission spectrum into the shorter-wave range and vice versa. For the development of a bioassay using the luminescence effect, this additionally opens up the possibility of carrying out different luminescence labels not only via the choice of substance, but also via the particle size. This provides an excellent basis for the optical coding of biomolecules in the context of bioarray development.
  • US Pat. No. 5,324,633 relates to bioarray methods for the detection of fluorescence-labeled receptors bound to biopolymers with the aid of a photon counter or confocal microscopy.
  • Xanthene fluorescent dyes with an excitation frequency of 450-650 ⁇ m for cell detection using labeled antibodies are described in US Pat. No. 5,066,580.
  • US Pat. Nos. 3,998,943, 3,996,345, 4,174,384, 4,199,559 and 4,261,968 disclose ligand receptor assays whose basic principle is to label a receptor and / or ligand with a fluorescent dye, the emission behavior of which is detected as a function of the ligand receptor binding.
  • US Pat. No. 5,319,209 discloses fluorescence probes, inter alia in the form of benzofuran isophthalate, which are suitable for measuring ion concentrations in cells.
  • the production of semiconductor nanocrystals or quantum dots with the corresponding optical properties is state of the art and variously described in the literature: Kortan et al., J. Am. Chem. Soc. Vol 112, 1327, 1990; Colvin et al., Nature, Vol. 370, 354, 1994; Murray et al., J. Am. Chem. Soc. Vol. 115, 8706, 1993; Hirai et al., J. Phys. Chem. B, Vol.
  • luminescent substances for the use of luminescent substances in bioanalytics, however, the actual synthesis is not the only decisive factor. At the same time, the possibility of covalently binding the luminescence markers to the corresponding biosubstances is also decisive.
  • functional groups are introduced predominantly in the form of N-hydroxysuccinimidyl esters or isothiocyanate functions, which form a bond with the amino groups of the biomolecules.
  • the functionalization of the quantum dots is basically carried out in two ways: firstly, the surfaces are reacted with functional mercapto compounds such as mercaptopropionic acid, dihydroliponic acid, mercaptoacetic acid, mercaptosilanes, which are then preferably coupled to the corresponding biomolecules via the carboxyl function (Gerion et al., J Phys. Chem. Vol. 105, 8861, 2001; Mattoussi et al., J. Am. Chem. Soc. Vol. 122, 12142, 2000; Chan et al., Science Vol 281, 2016, 1998; Mitchell et al ., J. Am. Chem. Soc. Vol.
  • the quantum dots are encapsulated in a polymer matrix or dendrimers (,, capping M ).
  • a polymer matrix or dendrimers (,, capping M ).
  • Le on et al. J. Am. Chem. Soc. Vol. 122, 12886, 2000), Sooklal et al. (Adv. Mater. Vol. 10, 1083, 1998) and Lakowicz et al. (J. Phys. Chem. Vol. 103, 7613, 1999) describe the encapsulation of the semiconductor nanocrystals with the aid of polyamido in dendrimers.
  • Quantum dots which are coated with mercapto components and diaminocarboxylic acids and semiconductor nanocrystals which are produced in the gas phase with the aid of a spray system are the subject of US Patents 6,114,038 and 5,906,670.
  • US Patents 5,293,050 and 5,354,707 disclose light-emitting semiconductor layers made of silicone for circuits in which the second silicone layer contains at least one quantum dot.
  • US Pat. No. 5,525,377 describes nanoparticles of doped semiconductor compounds 20 to 100 ⁇ in size, coated with polymethyl methacrylates, for use as cathode ray tubes or electroluminescent displays.
  • semiconductor nanocrystals in the form of ZnS, ZnSe, ZnTe, CdS, CdSe, CdTe; HgS, HgSe, HgTe, GaS, nAs, nP and InSb as an electron transport medium for the production of electroluminescent devices which emit visible light of different wavelengths when voltage is applied are disclosed in US Pat. No. 5,537,000.
  • Laser-amplifying crystals doped with transition metals, consisting of groups II and VI, are the subject of US Pat. No. 5,541,948.
  • a glass matrix doped with luminescence nanocrystals is described in US Pat. No. 5,585,640. Temperatures above 1000 ° C are required to manufacture the doped, prefabricated glass molds.
  • US Pat. No. 5,770,299 discloses semiconductor nanocrystals consisting of CdS and / or II-V components or II-VI semiconductor nanocrystals as pigments for paints. Solid phase synthesis of fluorescence-labeled peptide libraries on commercial silica gel beads are described in US Pat. No. 5,789,162.
  • Luminescence semiconductor nanocrystal probes for biological applications which are coated with silane derivatives and are capable of binding affinity molecules, are described in US Pat. No. 5,990,479.
  • US Patent 5,043,265 discloses fluorescence particles in the form of ZnS-Ag and Y 2 O z S-Eu as labels for immunoglobulins and polynucleotides.
  • Up-converting phosphors Another group of light-emitting substances the so-called up-converting phosphors, whose specialty is the emission of shorter-wave radiation compared to the excitation radiation.
  • Substances of this type are largely composed of compounds of oxygen and / or sulfur and / or fluorine with the lanthanoids or yttrium.
  • these substances For use in bioassay, these substances have the advantage that their absorption and emission frequencies are not disturbed by autofluorescence of the carrier systems, such as carrier particles or microtiter plates, a phenomenon that is still an unsolved problem in today's bioanalytics when using carrier systems of any kind represents.
  • U.S. Patents 5,674,698 and 5,698,397 disclose a number of molecular probes in the form of doped up-converting phosphors such as e.g. Na-yttrium fluoride, Na-yttrium fluoride, lanthanum fluoride, gadolinium fluoride and yttrium oxysulfides are described which are used in biological and other assays by means of laser excitation.
  • doped up-converting phosphors such as e.g. Na-yttrium fluoride, Na-yttrium fluoride, lanthanum fluoride, gadolinium fluoride and yttrium oxysulfides are described which are used in biological and other assays by means of laser excitation.
  • Up-converting phosphor particles encapsulated in polyacrylate microcarriers which are transparent to the excitation and emission frequencies and can covalently bind protein probes via functional groups, are described in US Pat. No. 5,132,242.
  • Up-converting phosphors for the detection of nucleic acid sequences or for the immunoassay have been described by Corstjens et al. (Clin. Chem. Vol. 47, 1885, 2001) and Niedbala et al. (Anal. Biochem. Vol. 293, 22, 2001), silane-coated up-converting phosphor by Hampl et al. (Anal. Biochem. Vol. 288, 176, 2001).
  • Luminescent metal porphyrins which can be used for the detection of biological substances are the subject of US Pat. No. 6,004,530.
  • the luminescence markers known from the prior art in the form of single molecules or nanocrystals have the disadvantage that their use requires preparations which are complex especially for the bioassay, both in terms of the time and the process engineering expenditure.
  • synthesis or preparation times of several hours to several days are necessary in connection with complex process engineering: working under a nitrogen inert gas atmosphere, distillation, working in organic media.
  • the products, if they are organic polymers have a pronounced auto-fluorescence, cf. Han et al., Listed above for reference.
  • the most serious limitation of the known luminescence systems is that usually only one or very few luminescence particles (semiconductor nanocrystals or up-converting phosphor crystal) are bound per biomolecule to be labeled. This limitation consequently reduces the sensitivity of the bioassay to detection. The same also applies to luminescence molecules, of which only a very small number can be bound per biomolecule, so that the signal emanating from a labeled bi-molecule is difficult to detect.
  • the luminescent substance can be inactivated by coupling it to the biomolecule (eg antibody).
  • the luminescence-labeled micro- or nanoparticles developed as an alternative are consistently luminescence markers bound to the surface of the particles, the production, use and detection of which are difficult; see: Fornusek and Vetv cka, "Polymeric Microspheres as Diagnostic Tools for Cell Surface Marker Tracing," in CRC Critical Reviews in Therapeutic Drug Carrier Systems, 2, pp. 137-174, 1986.
  • the article contains a critical overview of this technique, furthermore, given here for reference: Kaplan et al. (Bio- ⁇ himica et Biophysica Acta, Vol. 728, 112, 1983) and the U.S. Patents 3,853,987, 4,035,316, 4,105,598, 4,108,972, 4,224,198 and 4,326,008.
  • the object of the present invention is to circumvent the disadvantages of the luminescence carrier systems known from the prior art and to provide translucent, non-autofluorescent micro- and sub-microparticulate particles with adaptable porosity, which contain multiplex luminescent substances.
  • the possibility of encapsulating a large number of luminescent agents both in the form of molecules and also nanoparticles or colloids can surprisingly increase the detection sensitivity for biomolecules in the context of bioanalytics and diagnostics in such a way that the possibility of detecting individual molecules becomes possible.
  • a large number of optical coding of the biomolecules can be carried out.
  • This object is achieved according to the invention by encapsulating luminescent substances in a translucent matrix made of silica gel which do not impair the basic luminescence properties of the base substance. Furthermore, this object is achieved according to the invention by an inverse suspension process in which a mixture consisting of a silica gel sol and the luminescent substance is dispersed in a water-immiscible organic phase and then polycondensed. In this way, three-dimensionally cross-linked, pearl-shaped polymer supports are formed which contain the luminescent substance encapsulated.
  • Silica sols are produced according to the processes generally known from the prior art by hydrolysis of alkoxysilanes using dilute mineral acids (Dave et al. In: Immobilized Biomolecules in Analysis, ed. Cass and Ligler, Oxford University Press, 1998; WO 02/09125 AI) produced. Silicic acid orthoesters of aliphatic alcohols can be used as alkoxysilanes, preferably methyl, ethyl or propyl esters being used individually or as mixtures. The corresponding luminescent substances are added to the silica sol in the second step.
  • the reaction is carried out in an ultrasonic bath or with the aid of an ultrasonic sonotrode.
  • the sonication process usually takes half a minute.
  • the colloidally disperse mixture obtained in this way is then dispersed in an organic, water-immiscible solvent, as a rule with stirring. Bead-shaped sol droplets are formed, which then polycondense to three-dimensionally cross-linked silica gels by adding a dilute base.
  • the polarity properties of the sol and the organic dispersion phase are selected so that, on the one hand, a stable suspension is formed and, on the other hand, the added luminescent substance has a high affinity for the sol phase, so that there is a clear separation between the sol and organic phases and consequently the added luminescent compound is homogeneously distributed only in the sol phase.
  • the entire manufacturing process including the preparation of the silica gel brine, takes 20 to 50 minutes, depending on the approach.
  • the starting point for the synthesis of the luminescence particles are silica sols, which are formed by known methods by hydrolysis of suitable alkoxysilanes in an acidic, aqueous medium.
  • silica sols which are formed by known methods by hydrolysis of suitable alkoxysilanes in an acidic, aqueous medium.
  • this, together with a defined concentration of the silanes enables the production of completely transparent particles.
  • the concentrations of alkoxysilanes in the initial mixture are between 40 and 90 Vol. 9 -, preferably between 65 and 80% by volume.
  • silica brine obtained in this way can be stored for several days at freezing temperatures (approx. -18 ° C) or can optionally be processed immediately.
  • Another feature of the silica gel technology according to the invention is to vary the porosity of the particles obtained within a wide range, a parameter that no other method known from the prior art offers in this way.
  • the porosity of particulate carrier media plays a crucial role in all bioassays or separation processes insofar as the specific detectability of the analyte depends on its binding to the ligand or receptor immobilized on the carrier.
  • the extent and quality of this binding process is directly influenced by the accessible surface of the carrier.
  • the latter is determined directly by the porosity of the carrier.
  • this can be adjusted with the aid of the products and methods according to the invention by adding certain substances to the sol. These substances, commonly referred to as porogens, are added to the sol before dispersion. Substances that do not impair the absorption-emission behavior of the carrier are preferred as additives.
  • Examples of this which do not limit the invention are: polyethylene glycol, polyvinyl alcohol, polyacrylic acid, polyamino acids, polysaccharides, proteins or polyvinylpyrrolidone. They are encapsulated in the spherical particles during the dispersion and crosslinking process.
  • the volume fraction of the organic polymer solutions, which are all present as 1 to 10% aqueous solutions, is between 1 and 20% based on the sol phase.
  • Another parameter for setting the porosity results from the selection of the composition of the different di- or tetrasubstituted silane components.
  • gels made from purely tetrasubstituted esters generally have a lower porosity than brines or gels that were prepared with the addition of di- or tri-substituted ester compounds.
  • di- or trifunctional ester compounds By specifically adding the di- or trifunctional ester compounds, pore sizes in the range of 50-200 nm can be achieved.
  • concentration of the di- and trifunctional silanes is generally 1-10, preferably 1 to 5% by volume, based on the total silane concentration.
  • Another essential aspect of the products and methods according to the invention is to control the part size both via the type of mechanical stirring and via the viscosity of the silica sol.
  • the particle sizes in suspension polymerization are adjusted via the stirring speed in such a way that the particle size generally decreases with increasing stirring speed.
  • the relationship between these parameters also applies to the present invention, i.e., stirring speeds> 1000 rpm. generally lead to particle sizes ⁇ 50 ⁇ m, those of> 5000 rpm consistently to particle sizes ⁇ 10 ⁇ m.
  • dispersion tools are used, e.g. work according to the rotor-stator principle and a rotor speed of> 10,000 rpm. have (e.g.
  • Ultra-Turrax® required. Particle sizes in the range from 0.5 to 10 ⁇ m can also be achieved by treatment with ultrasound.
  • the viscosity of the sol also has a decisive influence on the particle sizes. Falling viscosity of the sol usually leads to an analog reduction particle sizes and vice versa: increasing viscosities generally lead to a partial increase in size.
  • the viscosities required to produce the products according to the invention with the desired particle sizes from 0.5 to 50 ⁇ m are in the range from 5 to 300 cp.
  • the corresponding luminescent marker is added in the subsequent step and mixed intimately with the sol, preferably with the aid of an ultrasound treatment.
  • Compounds which can be used as luminescent substances are those which, after absorption of radiation of a certain wavelength, are capable of emitting photons of a frequency different from the absorption frequency and which are able to form a homogeneous mixture with the silica gel sol. Substances of this type are described in many different ways in the literature cited as a reference.
  • luminescent molecules or markers are: fluorescein, rhodamine, coumarin, dansyl chloride, ethidium bromide, Texas Red, phycoerythrin, Oregon Green or Cascade Blue, furthermore those under the trade name BODIPY, SYBR Green, T0T0-1 or YOYO -1 known compounds and the derivatives of these products.
  • Compounds from the II-VI series such as, for example, come as semiconductor nanocrystals.
  • semiconductors from group IVA such as e.g. Germanium suitable.
  • Suitable examples of the up-converting phosphors are rare earth compounds or Group IIB elements such as: sodium yttrium fluoride, lanthanum fluoride, lanthanum oxysulfide, yttrium oxysulfide, yttrium fluoride, yttrium gallate, gadolinium fluoride, barium yttrium fluoride, gadolin and compounds of the above type doped with activator pairs such as ytterbium / erbium, ytterbium / thulium or ytterbium / holmium. Chelate compounds composed of erbium, neodymium, thulium, holmium and praseodymium are also suitable as up-converting phosphors.
  • luminescent proteins such as rhodopsin, the green fluorescent protein ("green fluorescent protein", GFP) and metal porphyrins can also be used as the luminescent substance.
  • GFP green fluorescent protein
  • metal porphyrins metal porphyrins
  • concentration of the luminescent substances added can be varied within a wide range, depending on the requirements placed on the relevant bioanalysis or diagnostics. As a rule, concentrations of 1-10 GewSs of the marker substance are sufficient to achieve a clear luminescence. These concentrations exceed the luminescence marker concentrations that can be used in the conventional assays per analyte by several orders of magnitude.
  • concentrations of the magnetic colloids are chosen so that the transparency of the particles with respect to the absorption and emission behavior of the luminescent markers is fundamentally not impaired. They are generally between 10 and 30% by weight based on the silica gel particles.
  • the silica gel wax marker mixtures are dispersed in an organic phase with stirring.
  • Suitable solvents are dispersing agents which are immiscible with water and which permit stable dispersion of the silica sol. Dispersing agents of this type are generally known from the prior art and are described in WO 02/09125 and by Laane et al. ("Biocatalysis in Organic Media", Laane et al. Ed., Elsevier, Amsterdam, pp 65, 1987).
  • Solvents which fulfill these properties are, for example, hexane, trichlorethylene, petroleum ether, toluene, chloroform, 1.1.1 Trichloroethane, carbon tetrachloride, heptane Mixtures of the above solvents, which have a density of about 1 g / cm 3 , are also suitable for dispersing.
  • the volume ratios of organic phase to hydrosol are generally 8: 1 to 30: 1.
  • one or more surface-active substances in the form of surfactants, dispersion stabilizers or emulsifiers can be added to the organic phase.
  • examples include: propylene oxide-ethylene oxide block copolymers, polyhydroxy fatty acid-polyethylene glycol block copolymers, polyethylene glycol ether derivatives, sorbitan fatty acid esters, block copolymers from castor oil derivatives, polyethylene glycol-castor oil derivatives, poly- lyoxyethylene sorbitan fatty acid esters, alkylphenylpolyethylene glycol derivatives, polyglycerol esters, modified polyesters, polyoxypropylene-ethylene diamine block copolymers, polyethylene glycols, polyoxyethylene, polyoxyethylene alcohol derivatives.
  • Substances of this type are commercially available, inter alia, under the trade name: Renex®, Estol®, Prisorine®, Hypermer®, Pluronic®, Tween®, Eumulgin®, Pripol®, Tetronic®, Brij®, Lameform®, Arlacel®, Span ®, Dehymuls®, Synperonic® or Triton®.
  • the surfactant concentrations relevant for the production of the particles are between 0.1 and 15%, preferably between 0.5 and 6% by volume or% by weight.
  • a dilute base is added to the brine during the dispersing process, as a result of which the former polycondenses into a solid gel.
  • the brine is usually fixed to the desired gel particles within a few seconds (3 to 20 seconds). Accordingly, the mechanical dispersing process only takes a few seconds.
  • Ammonia in the form of a 1 to 12% aqueous solution is preferably used as the base, other bases, such as e.g. In principle, NaOH, diethylamine or KOH can also be used.
  • the volume ratios of base to sol are usually between 1: 2 and 1: 4.
  • the entire particle production process including the encapsulation of the luminescent markers, is accomplished within one hour. This represents a time saving of up to 90% compared to all conventional processes for producing luminescent particles.
  • the manufacturing process is followed by several washes with alcohol and water.
  • the magnetic carriers obtained are which is usually kept in water.
  • the silica gel particles obtained can then be used directly for further functionalization.
  • the well-known activation and coupling methods for silica gel or silanized are used Carrier related. These include the reactions with functional alkoxysilanes, which have, for example, amino, epoxy, mercapto, isothio ⁇ yanate, acrylic or halogen groups.
  • activating or coupling agents are: 3-aminopropyl-triethoxysilane, 3-aminopropyltrimethoxysilane, 3-glycidyloxypropyltrimethoxysilane, 3-glycidyloxypropyl-methyl-diethoxysilane, 3-mercaptopropyl-trimethoxysilane, 3-isothiocyanyloxypropyl-3-isothiocyanethoxysilane, triethoxysilane.
  • Activation of the silica gel particles by means of photoactive agents for example those carrying arylazide or diazirine functions, which can first be coupled to the support by UV radiation and then react with the bioligand or the biomolecule, are also simple feasible.
  • Photoactive agents for example those carrying arylazide or diazirine functions, which can first be coupled to the support by UV radiation and then react with the bioligand or the biomolecule.
  • Substances of this type are, for example: N-hydroxysuccinimidyl-4-azidobenzoate, [2-nitro-4- [3- (trifluoromethyl) -3H-diazirin-3- yl] phenoxy] acetyl-N-hydroxysuccinimidate, N-hydroxysuccinimidyl- (4-azidophenyl) ⁇ 1,3 "-dithiopropionate, N- [m- [3- (trifluoromethyl) diazirin-3-yl] phenyl]
  • the use of the luminescence particles according to the invention extends to all areas of bioanalytics and diagnostics that use a color reaction that uses luminescence or radioactivity to detect or quantify specific substances or analytes.
  • the immunoassay in the form of radio or enzyme immunoassays, nucleic acid detection, proteome analysis, DNA sequencing, phage display, cell labeling, the nucleic acid array or cell labeling.
  • the particulate luminescence markers can be used in flow cytometry or in fluorescence-activated cell sorters (fluorescent-activated cell sorters, FACS ® ) or for testing DNA or protein libraries.
  • the particles obtained are then washed several times with anhydrous toluene and then reacted under an argon atmosphere with 5 ml of anhydrous toluene and 2 ml of 3-glycidyloxypropyltrimethoxysilane for 3 hours at 90 ° C. with stirring. Then it is washed five times with toluene and acetone.
  • 100 mg of the product obtained are then washed three times with 0.5 molar phosphate buffer, pH 8.5, and then incubated at 40 ° C. for 5 hours with 2 ml of the same buffer in which 10 mg of streptavidin are dissolved.
  • the product is then washed five times using a respective centrifugation step with 0.05 M phosphate buffer, pH 7.2.
  • the coupled product is exposed for 24 hours in 1% ethanol amine solution containing 0.1% serum albumin at room temperature. stored. This is followed by repeated washing with 0.05 Tris / HCl buffer, pH 8.0.
  • the result is a product that can be used for binding or labeling biotinylated biomolecules.
  • 0.5 ml of tetraethoxysilane are mixed with 0.1 ml of water and 0.08 ml of 0.1 M HC1 and sonicated for 10 minutes at room temperature in an ultrasonic bath.
  • 0.2 ml of the sol obtained are mixed with 5 mg (YYbEr) 2 0 2 S, which according to a specification by Hampl et al. (Anal. Biochem., Vol. 288, 176, 2001) was prepared, mixed and treated in an ultrasonic bath for 5 minutes.
  • 30 mg of magnetite powder (Bayferrox 318M, Bayer, FRG) are then added to the mixture. The mixture is sonicated again for 2 minutes.
  • the mixture is then dispersed with stirring (Ultra-Turrax) at 12,000 rpm in 3 ml of trichlorethylene in which 2% by volume of Dehymuls HRE7 ® and 0.5% by volume of Prisorine 3700 ® are dissolved. 0.08 ml of 6% aqueous ammonia solution are added during the dispersing process. The stirring is continued for a further 5 seconds. Separation and processing of the luminescent particles obtained is carried out analogously to Example 1. Luminescent particles with an average size of 6.7 ⁇ m are obtained.
  • the product which was dried in vacuo for 3 hours, is washed five times with dried toluene after magnetic separation in each case and then refluxed 12 hours after the addition of 3 ml of toluene and 0.25 ml of 3-aminopropyltriethoxysilane.
  • the magnetic particles are again separated magnetically and washed three times with about 5 ml of toluene and chloroform. This is followed by drying under vacuum for several hours.
  • the amino-modified product is then reacted with 6% glutaraldehyde solution in 4 ml of 0.1 M Na carbonate buffer, pH 9.0, for 2 hours at 35 ° C. It is then intensively rewashed with 0.1 M phosphate buffer, pH 7.2.
  • Biomolecules carrying amino groups such as proteins, peptides, can then be attached to the aldehyde-functionalized luminescent particles obtained by the known methods or coupled at the 5 'end with amino group-substituted nucleic acids or oligonucleotides according to the known methods.
  • the luminescent particles functionalized in this way can be used as probes in protein or nucleic acid arrays.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Luminescent Compositions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Silicon Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP03720372A 2002-03-30 2003-03-27 Particules de silicagel luminescentes, spheriques et non autofluorescentes a intensites et frequences d'emission variables Expired - Lifetime EP1490691B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10214019 2002-03-30
DE10214019A DE10214019A1 (de) 2002-03-30 2002-03-30 Lumineszierende, sphärische, nicht autofluoreszierende Silicagel-Partikel mit veränderbaren Emissionsintensitäten und -frequenzen
PCT/EP2003/003163 WO2003083481A2 (fr) 2002-03-30 2003-03-27 Particules de silicagel luminescentes, spheriques et non autofluorescentes a intensites et frequences d'emission variables

Publications (2)

Publication Number Publication Date
EP1490691A2 true EP1490691A2 (fr) 2004-12-29
EP1490691B1 EP1490691B1 (fr) 2009-01-21

Family

ID=28050954

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03720372A Expired - Lifetime EP1490691B1 (fr) 2002-03-30 2003-03-27 Particules de silicagel luminescentes, spheriques et non autofluorescentes a intensites et frequences d'emission variables

Country Status (8)

Country Link
US (1) US20050147974A1 (fr)
EP (1) EP1490691B1 (fr)
JP (1) JP2005528466A (fr)
CN (1) CN1643379A (fr)
AT (1) ATE421696T1 (fr)
AU (1) AU2003223998A1 (fr)
DE (2) DE10214019A1 (fr)
WO (1) WO2003083481A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0400235D0 (en) * 2004-01-07 2004-02-11 Univ Sunderland Nanoparticles as agents for imaging finger prints
EP2305775A3 (fr) * 2004-10-29 2011-06-08 Molecular Probes, Inc. Nanocristaux fluorescents fonctionnalisés et procédés pour leur préparation et utilisation
EP1841819A1 (fr) * 2004-12-07 2007-10-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Composites spheriques emprisonnant des nanoparticules, procedes de preparation et utilisations associes
WO2006070582A1 (fr) * 2004-12-09 2006-07-06 Techno Network Shikoku. Co., Ltd. Procede de preparation d’une sphere de silice contenant une molecule marquee
JP2006305485A (ja) * 2005-04-28 2006-11-09 Hitachi Maxell Ltd 磁性担体の製造方法
NZ565663A (en) 2005-08-09 2011-03-31 Univ Sunderland The use of hydrophobic silica particles in detecting and identifying fingerprints
JP5400297B2 (ja) * 2005-12-27 2014-01-29 古河電気工業株式会社 蛍光ナノシリカ粒子、ナノ蛍光材料、それを用いたバイオチップ及びそのアッセイ法
WO2008035569A1 (fr) * 2006-09-19 2008-03-27 Konica Minolta Medical & Graphic, Inc. réactif de détection de biomolécule et procédé de détection de biomolécule utilisant le réactif
US8053744B2 (en) * 2009-04-13 2011-11-08 Src, Inc. Location analysis using nucleic acid-labeled tags
FR2952436B1 (fr) * 2009-11-10 2014-10-31 Commissariat Energie Atomique Materiau et procede pour pieger, detecter et quantifier des composes aromatiques heterocycliques et autres.
ES2621128T3 (es) 2010-02-02 2017-07-03 Ventana Medical Systems, Inc. Composición y procedimiento para la estabilización de partículas fluorescentes
US20130150265A1 (en) * 2010-02-09 2013-06-13 Robert Balog Chemical synthesis using up-converting phosphor technology and high speed flow cytometry
US8703493B2 (en) 2010-06-15 2014-04-22 Src, Inc. Location analysis using fire retardant-protected nucleic acid-labeled tags
US8716027B2 (en) 2010-08-03 2014-05-06 Src, Inc. Nucleic acid-labeled tags associated with odorant
EP2601307A4 (fr) 2010-08-06 2014-01-01 Capitalbio Corp Dosage à base de micropuces comprenant des particules, destiné à analyser des interactions moléculaires
WO2012055069A1 (fr) * 2010-10-27 2012-05-03 Capitalbio Corporation Molécules marquées par un luminophore couplées à des particules pour des dosages sur micropuce
FR2993798B1 (fr) * 2012-07-25 2015-03-06 Commissariat Energie Atomique Procede de marquage d'un substrat metallique par incorporation de particules inorganiques luminescentes
CN103760355B (zh) 2013-12-05 2015-09-16 博奥生物集团有限公司 微阵列芯片检测中核苷酸序列的颗粒标记方法
DE102014110573A1 (de) 2014-07-25 2016-01-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Mit einer Signatur auf Basis von superparamagnetischen und/oder weichmagnetischen Nanopartikeln versehener Gegenstand, Verfahren zu dessen Herstellung und Verwendung von superparamagnetischen und/oder weichmagnetischen Nanopartikeln zum Sichern von Gegenständen gegen Fälschung und Nachahmung
CN105419778B (zh) * 2015-12-22 2017-11-14 重庆益新阳工贸有限公司 一种含有石蜡的量子点复合材料及其制备方法
PL3424056T3 (pl) 2016-02-29 2024-08-05 Lord Corporation Dodatek do cieczy magnetoreologicznych
US10941057B2 (en) * 2017-04-28 2021-03-09 U.S. Environmental Protection Agency Highly tunable fluorescent core-shell particles for environmental release simulation and tracking applications
CN109540878B (zh) * 2018-11-12 2021-07-27 安庆师范大学 一种检测钡离子的试剂盒及其检测方法
WO2021017904A1 (fr) * 2019-07-31 2021-02-04 Auiset Biotechnology Co. Ltd. Fabrication de nanoparticules fluorescentes et leurs conjugués pour le diagnostic in vitro et in vivo
CN114032086B (zh) * 2020-12-25 2023-11-17 武汉大学 一种长余辉纳米探针组合在检测细菌生物被膜中的应用
CN115261013B (zh) * 2022-07-01 2024-06-14 西安邮电大学 一种稀土发光材料及其制备方法与应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853987A (en) * 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3998943A (en) * 1973-10-02 1976-12-21 Syva Company Double receptor fluorescent immunoassay
US4108972A (en) * 1974-03-15 1978-08-22 Dreyer William J Immunological reagent employing radioactive and other tracers
DE2426919C3 (de) * 1974-06-04 1981-07-16 Philippe Edouard Jean Leon Alexis Puteaux Gravisse PhotolumineszierendesBaumaterial und ein Verfahren zu dessen Herstellung
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4199559A (en) * 1974-08-12 1980-04-22 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4174384A (en) * 1975-06-30 1979-11-13 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4035316A (en) * 1975-11-24 1977-07-12 California Institute Of Technology Cell specific, variable density, polymer microspheres
US4326008A (en) * 1976-08-27 1982-04-20 California Institute Of Technology Protein specific fluorescent microspheres for labelling a protein
US4235869A (en) * 1978-05-16 1980-11-25 Syva Company Assay employing a labeled Fab-fragment ligand complex
US4224198A (en) * 1978-05-26 1980-09-23 California Institute Of Technology Protein specific polymeric immunomicrospheres
US4261968A (en) * 1979-05-10 1981-04-14 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4666862A (en) * 1984-08-14 1987-05-19 Ortho Diagnostic Systems Inc. Fluorescent energy transfer with phycobiliproteins
JPS61246748A (ja) * 1985-04-24 1986-11-04 Konishiroku Photo Ind Co Ltd ハロゲン化銀カラ−写真感光材料
DE3677364D1 (de) * 1985-08-05 1991-03-07 Univ Leiden Markierte makromolekuele; verfahren zu ihrer herstellung und ihre verwendung in immunologischen oder immunocytochemischen testen.
US5132242A (en) * 1987-07-15 1992-07-21 Cheung Sau W Fluorescent microspheres and methods of using them
US5066580A (en) * 1988-08-31 1991-11-19 Becton Dickinson And Company Xanthene dyes that emit to the red of fluorescein
KR930011971B1 (ko) * 1991-01-29 1993-12-23 삼성전자 주식회사 색신호 경계면 보정장치
CA2118806A1 (fr) * 1991-09-18 1993-04-01 William J. Dower Methode pour la synthese de diverses series d'oligomeres
JP2970967B2 (ja) * 1991-11-20 1999-11-02 浜松ホトニクス株式会社 蛍光性プローブ試薬を用いた細胞内イオン濃度測定法
US5262357A (en) * 1991-11-22 1993-11-16 The Regents Of The University Of California Low temperature thin films formed from nanocrystal precursors
US5505928A (en) * 1991-11-22 1996-04-09 The Regents Of University Of California Preparation of III-V semiconductor nanocrystals
JPH07502479A (ja) * 1991-11-22 1995-03-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 自己集合性単一層を使って固体無機表面に共有結合した半導体微少結晶
US5324633A (en) * 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
US5698397A (en) * 1995-06-07 1997-12-16 Sri International Up-converting reporters for biological and other assays using laser excitation techniques
US5674698A (en) * 1992-09-14 1997-10-07 Sri International Up-converting reporters for biological and other assays using laser excitation techniques
US5293050A (en) * 1993-03-25 1994-03-08 International Business Machines Corporation Semiconductor quantum dot light emitting/detecting devices
US6048616A (en) * 1993-04-21 2000-04-11 Philips Electronics N.A. Corp. Encapsulated quantum sized doped semiconductor particles and method of manufacturing same
GB9323498D0 (en) * 1993-11-15 1994-01-05 Isis Innovation Making particles of uniform size
US5527711A (en) * 1993-12-13 1996-06-18 Hewlett Packard Company Method and reagents for binding chemical analytes to a substrate surface, and related analytical devices and diagnostic techniques
US5537000A (en) * 1994-04-29 1996-07-16 The Regents, University Of California Electroluminescent devices formed using semiconductor nanocrystals as an electron transport media and method of making such electroluminescent devices
US5541948A (en) * 1994-11-28 1996-07-30 The Regents Of The University Of California Transition-metal doped sulfide, selenide, and telluride laser crystal and lasers
US5985353A (en) * 1994-12-01 1999-11-16 University Of Massachusetts Lowell Biomolecular synthesis of quantum dot composites
US5585640A (en) * 1995-01-11 1996-12-17 Huston; Alan L. Glass matrix doped with activated luminescent nanocrystalline particles
DE19541028C2 (de) * 1995-11-05 1998-01-22 Daimler Benz Ag Effektlack mit Pigmenten, die eine Kennzeichnung tragen, sowie Verfahren zu seiner Herstellung
US6207397B1 (en) * 1996-04-18 2001-03-27 Ariad Pharmaceuticals, Inc. In vitro fluorescence polarization assay
US6004530A (en) * 1996-06-04 1999-12-21 Roche Diagnostics Gmbh Use of metallo-porphyrin conjugates for the detection of biological substances
DE19730359A1 (de) * 1997-07-15 1999-01-21 Boehringer Mannheim Gmbh Integriertes Verfahren und System zur Amplifizierung und zum Nachweis von Nukleinsäuren
US7348181B2 (en) * 1997-10-06 2008-03-25 Trustees Of Tufts College Self-encoding sensor with microspheres
US6322901B1 (en) * 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
US5990479A (en) * 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6326144B1 (en) * 1998-09-18 2001-12-04 Massachusetts Institute Of Technology Biological applications of quantum dots
US6114038A (en) * 1998-11-10 2000-09-05 Biocrystal Ltd. Functionalized nanocrystals and their use in detection systems

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03083481A3 *

Also Published As

Publication number Publication date
AU2003223998A1 (en) 2003-10-13
EP1490691B1 (fr) 2009-01-21
ATE421696T1 (de) 2009-02-15
WO2003083481A3 (fr) 2004-03-25
US20050147974A1 (en) 2005-07-07
CN1643379A (zh) 2005-07-20
AU2003223998A8 (en) 2003-10-13
DE50311117D1 (de) 2009-03-12
WO2003083481A2 (fr) 2003-10-09
JP2005528466A (ja) 2005-09-22
DE10214019A1 (de) 2003-10-16

Similar Documents

Publication Publication Date Title
EP1490691B1 (fr) Particules de silicagel luminescentes, spheriques et non autofluorescentes a intensites et frequences d'emission variables
US8168447B2 (en) Multiple component nanoparticles for multiplexed signaling and optical encoding
US6207392B1 (en) Semiconductor nanocrystal probes for biological applications and process for making and using such probes
Yan et al. Dye-doped nanoparticles for bioanalysis
US6548171B1 (en) Fluorescent nanocrystal-embedded microspheres for fluorescence analyses
JP4638128B2 (ja) 水性媒体における増強された分散性を有する、表面が修飾された半導性および金属性のナノ粒子
Ma et al. Synthesis and application of quantum dot-tagged fluorescent microbeads
Zhong et al. Preparation and application of functionalized nanoparticles of CdSe capped with 11-mercaptoundecanoic acid as a fluorescence probe
EP1483203B1 (fr) Nanoparticules oxydiques modifiees pourvues d'inclusions hydrophobes, procedes de production et d'utilisation desdites particules
JPWO2003060037A1 (ja) 蛍光色素分子含有シリカ球
Gelamos et al. Up-converter nanophosphor Y2O2S: Er, Yb aminofunctionalized containing or not spherical silica conjugated with BSA
Sathe et al. Development of dual-function microbeads embedded with quantum dots and iron oxide nanocrystals for biomedical applications
WO2002099425A2 (fr) Sonde
Hilliard Fluorescent dye-doped silica nanoparticles for bioanalysis
Yao et al. FloDots for Bioimaging and Bioanalysis
Yao et al. 12 FloDots for Bioimaging

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040915

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MAGNAMEDICS GMBH

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MAGNAMEDICS GMBH

17Q First examination report despatched

Effective date: 20070208

17Q First examination report despatched

Effective date: 20070208

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MUELLER-SCHULTE, DETLEF P.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REF Corresponds to:

Ref document number: 50311117

Country of ref document: DE

Date of ref document: 20090312

Kind code of ref document: P

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: MAGNAMEDICS GMBH

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ZIMMERLI, WAGNER & PARTNER AG

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: MAGNAMEDICS GMBH

Effective date: 20090325

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090502

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090121

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090121

REG Reference to a national code

Ref country code: IE

Ref legal event code: FD4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090421

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090622

REG Reference to a national code

Ref country code: FR

Ref legal event code: CA

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090331

Ref country code: IE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090121

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090121

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090121

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090121

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: MAGNAMEDICS GMBH

Free format text: MAGNAMEDICS GMBH#DENNEWARTSTRASSE 25-27#52068 AACHEN (DE) -TRANSFER TO- MAGNAMEDICS GMBH#DENNEWARTSTRASSE 25-27#52068 AACHEN (DE)

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090121

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090121

26N No opposition filed

Effective date: 20091022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090421

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20100325

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20100311

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20100326

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090422

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090327

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090121

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110327

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110331

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110327

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20170322

Year of fee payment: 15

Ref country code: NL

Payment date: 20170321

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20170321

Year of fee payment: 15

Ref country code: GB

Payment date: 20170322

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20180529

Year of fee payment: 16

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20180401

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20180327

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180327

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180331

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 50311117

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191001